Hisamitsu Pharmaceutical Co., Inc. (FRA:HPX)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.28B +25.0% |
| Revenue (ttm) | 884.04M +4.5% |
| Net Income | 103.90M -11.9% |
| EPS | 1.45 -9.1% |
| Shares Out | n/a |
| PE Ratio | 21.95 |
| Forward PE | n/a |
| Dividend | 0.35 (1.11%) |
| Ex-Dividend Date | Aug 28, 2025 |
| Volume | n/a |
| Average Volume | n/a |
| Open | 31.20 |
| Previous Close | 31.40 |
| Day's Range | 31.20 - 31.20 |
| 52-Week Range | 21.40 - 35.60 |
| Beta | n/a |
| RSI | 45.89 |
| Earnings Date | Apr 13, 2026 |
About FRA:HPX
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asi... [Read more]
Financial Performance
In fiscal year 2026, FRA:HPX's revenue was 163.02 billion, an increase of 4.50% compared to the previous year's 156.01 billion. Earnings were 19.16 billion, a decrease of -11.94%.
Financial numbers in JPY Financial StatementsNews
Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO
Japan's Hisamitsu Pharmaceutical is planning to take the company private in a management buyout for nearly 400 billion yen ($2.55 billion), it said in a filing late on Tuesday.